Heru, which is building a tool that uses AI and commercial AR/VR headsets to diagnose eye conditions and vision loss, raises $30M Series A led by D1 Capital
Conor Hale / FierceBiotech : Source: Business Wire .
Context & Ripple Effects
Heru's $30M Series A lands in a funding arc that eye-care AI has been building since IDx raised its $33M Series A in 2018 — capital that later returned as Digital Diagnostics' $75M Series B led by KKR. Heru's differentiator is hardware: instead of dedicated diagnostic equipment, its software runs AI vision tests on commercial AR/VR headsets.
The raise also sits inside a broader 2021 wave of AI-on-new-form-factor diagnostics — Cleerly's cardiac imaging Series B and Hyperfine's portable AI MRI round being adjacent data points — with D1 Capital taking an early-stage position even as its late-stage private pace slows.
First-order effects
- Heru gains the runway to validate and commercialize a diagnostic tool whose core cost advantage is that it runs on headsets clinics and consumers may already own, rather than proprietary exam hardware.
- D1 Capital secures an early position in AI diagnostics at Series A pricing, a segment where eye care has already produced a $75M+ follow-on round for IDx/Digital Diagnostics.
Second-order effects
- Digital Diagnostics, the best-funded incumbent in AI eye diagnostics, now faces a rival whose hardware-light model undercuts the dedicated-device economics its platform was built around.
- Commercial AR/VR headset makers gain a new medical vertical: every diagnostic app like Heru's turns consumer headsets into clinical-grade screening devices, expanding their addressable market beyond gaming and productivity.
Third-order effects
- If Heru's model holds, AI diagnostics decouples from dedicated clinical hardware — screening moves into consumer devices, and the regulatory and reimbursement pathways IDx pioneered for autonomous eye diagnosis become the template software-on-headsets players must clear.
- Capital formation in AI diagnostics consolidates around a repeatable pattern — Series A validation, then nine-figure growth rounds from crossover funds like D1 and KKR — shaping which diagnostic categories get built first.
The trend: AI diagnostics is migrating from dedicated medical hardware onto consumer devices like AR/VR headsets, with crossover capital funding the shift from eye care outward into other specialties.